Eyeworld

67 EW CORNEA May 2017 placebo group reported a pain score of zero 1 day after surgery. Dr. Wirostko said feedback from the clinical investigators and patients about the drug and delivery method has been very positive. "The patient was getting a bolus dose of steroids immediately follow- ing the cataract surgery so on day 1, we saw remarkable improvements in both inflammation and pain. The investigators were impressed with just how white, quiet, and comfort- able their patients were in the active arms as early as the first day post- op," she said. Dr. Wirostko described Eye- Gate's iontophoresis system as a different way to think about drug delivery and dosing. "It's not like a regular drug dose; you're controlling the amount of drug delivered both by duration of exposure and the amount of current over that short 1- to 2-minute time period," she said. Dr. Wolsey said she finds Eye- Gate's iontophoresis system to be a "very interesting concept, especially because right now after cataract surgery, we put patients on eye drops for weeks, in which cost and compliance become issues." Thus, Dr. Wolsey continued, if there was a quick, easy treatment to get drugs into the eye without drops, "that would be quite revolutionary." "Everyone is looking at putting intracameral injections in the eye, which can work but come with an- other host of problems. They're also looking at combination eye drops, so they're not putting as many in [the patient's] eye, but that means people are using an antibiotic drop for 3–4 weeks, which I don't think is a great use of antibiotics due to resistance, so nothing we have is really perfect right now. I think if we can limit use of drops and it's a couple of easy visits to the clinic for treatment, it could be quite impres- sive," Dr. Wolsey said. Dr. Wirostko said EyeGate hopes to submit a New Drug Application and supplement for the iontophore- sis system in early 2018 to the U.S. Food and Drug Administration. The Ocular Bandage Gel, she said, should see a device submission by late 2017 or early 2018. EW Editors' note: Dr. Wirostko has finan- cial interests with EyeGate. Dr. Wolsey does not have any financial interests related to her comments. Contact information Wirostko: bwirostko@eyegatepharma.com Wolsey: dwolsey@theeyeinstitute.com EACH WEEK, OIS INTERVIEWS THE LEADERS OF OPHTHALMIC INNOVATION The conversations continue between the bi-annual OIS meetings. Subscribe for free, and listen in on weekly one-on-one candid conversations between Tom Salemi and the innovators changing the face of ophthalmology. VISIT OUR WEBSITE FOR OUR COMPLETE LINEUP OF PODCASTS WWW.OIS.NET/PODCASTS

• Blank Page
• Blank Page (1)
• Blank Page (2)